Big Data Offer Opportunity for Research and Learning in Healthcare

Published Nov 6, 2019

Copenhagen, Denmark—6 November 2019—ISPOR, the professional society for health economics and outcomes research—held its third plenary session at ISPOR Europe 2019, “Big Data Healthcare: Endless Opportunities for Research and Learning," this morning in Copenhagen, Denmark.

ISPOR Europe 2019 Plenary 3

Big data present a tremendous opportunity for the measurement and reporting of quality in healthcare that can enhance insight and decision making. Healthcare data vary and include discrete coded data elements, images of diagnostics tests, and unstructured clinical notes. This type of high-volume and high-variety information demands innovative forms of information processing. In this session, panelists discussed a number of examples where experts are effectively using big data and for research and to drive learning at the healthcare system level.

Panelists for this session included:

  • Dorte Gyrd-Hansen, PhD, MSc, Danish Centre for Health Economics,University of Southern Denmark, Odense, Denmark
  • Laura Hatfield, PhD, Harvard Medical School, Boston, MA, USA
  • Jeremy Rassen, ScD, Aetion, Inc, New York, NY, USA
  • Michal Rosen-Zvi, PhD, IBM Research, The Hebrew University, Jerusalem, Israel

Dr Rassen believes that the debate over randomized controlled trials (RCTs) versus real-world evidence (RWE) is a false dichotomy. He argued that, rather than being an “either/or situation,” RWE can augment and extend RCT evidence. Rassen noted that the issue is not one of study methodology, but about establishing causality, and that both RCTs and RWE can “allow you to climb the causal ladder.” He noted that if researchers apply “principled process” that RWE can be equally effective to RCTs. Rassen identified principled process as including (a) thoughtful appropriateness assessment, (b) verification checks for real-world data reliability, (c) target-trial paradigm, and (d) transparency guidelines (as noted in the ISPOR/ISPE joint publication). He stressed that without application of principled process, RWE may not be considered regulatory grade. He also noted that cases remain where RCTs are better suited, such as placebo-controlled pivotal trials and where comparison is inappropriate for RWE.

Dr Hatfield spoke about how we can “know what works” in a sea of healthcare ideas. She pointed out that experimentation is everywhere, yet often RCTs are impractical for assessment. Healthcare produces much data through billing claims and electronic health records and Hatfield noted that this invites “quasi-experimental” analyses. She also provided an overview of “difference in differences” (aka “diff-in-diff”) methodology that attempts to mimic a controlled trial by using observational data.

Dr Rosen-Zvi spoke about how electronic medical records can be used to provide better healthcare. She discussed the transformative power of machine learning and stated that it has both technical and nontechnical challenges. The nontechnical challenges identified by 180 experts included regulatory, privacy and data protection, user acceptance and public opinion, lack of standardization, legal, and availability of skilled artificial intelligence (AI) experts. Rosen-Zvi illustrated the promise of AI with an example where AI improved breast cancer detection.

There was agreement among the panelists that the opportunities for big data in healthcare are vast and the challenges are great. New methods are needed to harness the potential for these data to have real impact.

ISPOR is recognized globally as the leading professional society for health economics and outcomes research and its role in improving healthcare decisions. ISPOR Europe 2019 expects to draw more than 5000 healthcare stakeholders with an interest in HEOR, including researchers and academicians, assessors and regulators, payers and policymakers, the life sciences industry, healthcare providers, and patient engagement organizations.

Additional information on the conference can be found at:
Conference Information | Program and Presentations | #ISPOREurope | Sponsors | Exhibitors | News and Press

###

 

ABOUT ISPOR
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Web: www.ispor.org | LinkedIn: www.linkedin.com/company/ispororg | Twitter: www.twitter.com/ispororg (@ISPORorg) | YouTube: www.youtube.com/ispororg | Facebook: www.facebook.com/ispororg | Instagram: www.instagram.com/ispororg

Related Stories

ISPOR Europe 2019 Convened More Than 5500 Healthcare Stakeholders in the Society’s Largest Conference To Date

Nov 7, 2019

ISPOR concluded its ISPOR Europe 2019 conference yesterday in Copenhagen, Denmark. The conference convened more than 5500 global healthcare stakeholders and HEOR thought leaders representing more than 90 countries. The record attendance of ISPOR Europe 2019 marks the Society’s largest conference to date.

Is the Subscription-Based Model for Drug Reimbursement the Future?

Nov 6, 2019

ISPOR explored the topical issue of the subscription-based model for drug reimbursement this morning during the session, “Subscription-Based Model for Drug Reimbursement: A Fad or the Future?”, at ISPOR Europe 2019 in Copenhagen, Denmark.

Bridging the Gap Between Evidence Requirements for Medical Device and Coverage/Reimbursement Decisions

Nov 5, 2019

ISPOR explored the issue of medical devices and the evolving demands for evidence requirements and assessments in the session, “The Evolving Demands for Medical Device Evidence Development: What the Future Holds.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×